ARK Innovation ETF vs Zoetis Inc — how do they compare? ARK Innovation ETF trades at $81.33, while Zoetis Inc trades at $73.52 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while ARK Innovation ETF pays none, and ARK Innovation ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| ARKK | ZTS | |
|---|---|---|
52-Week High | $92.50 | $156.76 |
52-Week Low | $63.52 | $71.91 |
Market Cap | — | $31.14B |
Sector | — | Health |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Signals from Pluang's Aura AI — not financial advice
ARKK trades at $81.22, up 0.94% today, with a bullish technical signal from moving averages but a neutral stance from oscillators. The ETF's concentrated portfolio in disruptive innovation faces mixed sentiment, with recent news highlighting both buying activity in AI stocks like CoreWeave and concerns over high fees and underperformance versus the S&P 500. Key resistance is at $82, with support at $79.
Outlook remains volatile; ARKK offers exposure to high-growth themes like AI and space technology but carries significant concentration risk and fee drag. Investment opportunity hinges on successful bets in unprofitable ventures, while risks include dependency on Tesla and SpaceX performance and broader market shifts away from speculative growth.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Trailing returns across standard periods
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →